V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 250006779 | 250009601 | 1.86 | null | Palliative (P) | 2015-09-21 | 2015-09-21 | RUXOLITINIB | N | N | 250030247 | RUXOLITINIB |
| 250006780 | 250004792 | 1.65 | 57 | Palliative (P) | 2018-07-08 | 2018-07-08 | RUXOLITINIB | null | N | 250030251 | RUXOLITINIB |
| 250006781 | 250004793 | 1.88 | 67.3 | Curative (C) | 2017-08-16 | 2017-09-08 | Dasatinib | null | null | 250030252 | IMATINIB |
| 250006782 | 250004794 | null | 63 | Palliative (P) | 2018-04-23 | 2018-04-30 | THALIDOMIDE | N | N | 250030256 | BUSULPHAN |
| 250006783 | 250004794 | 1.81 | 51 | Palliative (P) | 2017-10-25 | 2017-10-25 | Dasatinib | N | N | 250030256 | RUXOLITINIB |
| 250006784 | 250004795 | 1.61 | 59.9 | Disease modification (D) | 2016-08-20 | 2016-08-23 | RAVVA TRIAL | N | N | 250030261 | PEG INTERFERON |
| 250006785 | 250004796 | 1.67 | 91 | Palliative (P) | null | 2014-03-06 | DA | N | N | 250030262 | IMATINIB |
| 250006786 | 250004796 | 1.57 | 0 | Curative (C) | 2015-01-17 | 2015-01-22 | RUXOLITINIB | 02 | N | 250030262 | BENDAMUSTINE + RITUXIMAB |
| 250006787 | 250004796 | 0 | 52.8 | Palliative (P) | 2016-12-02 | 2016-12-02 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 250030262 | PEG INTERFERON |
| 250006788 | 250004796 | null | 67.4 | null | 2015-09-22 | 2015-09-22 | ANAGRELIDE | 02 | null | 250030262 | BUSULPHAN |
| 250006789 | 250004796 | null | 72.2 | Adjuvant (A) | 2016-12-22 | 2016-12-23 | PEG INTERFERON | 02 | N | 250030262 | RUXOLITINIB |
| 250006790 | 250004796 | 1.64 | 0 | Adjuvant (A) | 2014-09-22 | 2014-09-23 | CHOP R - 21 days | 2 | N | 250030262 | AML18 TRIAL |
| 250006791 | 250004796 | 0 | 0 | Not known (9) | 2013-11-24 | 2013-12-09 | CHOP R - 21 days | N | N | 250030262 | ANAGRELIDE |
| 250006792 | 250004797 | 1.75 | null | Palliative (P) | 2015-04-15 | 2015-05-19 | RUXOLITINIB | N | N | 250030278 | THALIDOMIDE |
| 250006793 | 250004798 | 1.78 | null | null | 2018-01-31 | 2018-02-01 | RUXOLITINIB | Y | N | 250030279 | TRIAL |
| 250006794 | 250009604 | 0 | 59.8 | Disease modification (D) | 2013-12-01 | 2013-12-01 | Rituximab | N | N | 250030280 | BENDAMUSTINE + RITUXIMAB |
| 250006795 | 250004799 | 1.77 | 71 | Disease modification (D) | 2015-04-25 | 2015-04-25 | RUXOLITINIB | 2 | N | 250030282 | RUXOLITINIB |
| 250006796 | 250009605 | 1.65 | 0 | Disease modification (D) | 2018-01-01 | 2018-01-01 | HLH Consol Etop/Dexamethasone | Y | N | 250030285 | RUXOLITINIB |
| 250006797 | 250009605 | 1.73 | 62 | Palliative (P) | 2017-05-19 | 2017-06-02 | ANAGRELIDE | 1 | N | 250030285 | BENDAMUSTINE + RITUXIMAB |
| 250006798 | 250004800 | 0 | 65.1 | Curative (C) | 2015-05-02 | 2015-05-07 | RUXOLITINIB | N | N | 250030294 | RUXOLITINIB |
| 250006799 | 250004800 | null | 20.4 | Neo-adjuvant (N) | 2014-08-17 | 2015-04-25 | RUXOLITINIB | 02 | null | 250030294 | BUSULPHAN |
| 250006800 | 250004800 | 1.53 | null | Not known (9) | 2016-03-11 | 2016-03-11 | BUSULFAN | 02 | N | 250030294 | CAP |
| 250006801 | 250004801 | null | 59.5 | Neo-adjuvant (N) | 2013-09-24 | 2013-09-24 | PEG INTERFERON | N | N | 250030307 | RUXOLITINIB |
| 250006802 | 250004802 | 1.53 | 77.15 | Curative (C) | 2015-06-22 | 2015-06-22 | ANAGRELIDE | N | N | 250030308 | PEG INTERFERON |
| 250006804 | 250004804 | 1.6 | null | Disease modification (D) | 2013-06-02 | 2013-06-12 | BUSULFAN | N | N | 250030320 | AZACITIDINE |
| 250006805 | 250004805 | 1.64 | 0 | Palliative (P) | 2014-10-22 | 2014-10-31 | RUXOLITINIB | N | N | 250030322 | RUXOLITINIB |
| 250006806 | 250004806 | 1.52 | 88 | Palliative (P) | null | 2014-08-12 | Rituximab | N | N | 250030325 | BUSULPHAN |
| 250006807 | 250004806 | 1.69 | 0 | Palliative (P) | 2015-10-21 | 2015-10-21 | RUXOLITINIB | 2 | N | 250030325 | RAVVA TRIAL |
| 250006808 | 250004806 | 0 | 54.6 | Neo-adjuvant (N) | null | 2017-12-18 | Rituximab (Maintenance) | 2 | N | 250030325 | RUXOLITINIB |
| 250006809 | 250004807 | 1.6 | 63 | Disease modification (D) | 2014-03-23 | 2014-03-23 | RUXOLITINIB | N | N | 250030332 | RUXOLITINIB |
| 250006810 | 250009608 | 1.59 | null | Palliative (P) | 2016-07-04 | 2016-07-04 | Rituximab | N | N | 250030333 | LENALIDOMIDE |
| 250006811 | 250009608 | 1.56 | null | Palliative (P) | 2016-11-17 | 2016-11-27 | RUXOLITINIB | N | N | 250030333 | CHOP R |
| 250006812 | 250009608 | 0 | 56.4 | Disease modification (D) | 2013-04-07 | 2013-04-13 | RUXOLITINIB | N | N | 250030333 | RITUXIMAB |
| 250006813 | 250009608 | 1.67 | 79 | null | 2017-09-25 | 2017-09-25 | Busulfan Oral | 02 | N | 250030333 | PEG INTERFERON |
| 250006814 | 250004808 | 0 | 0 | Palliative (P) | 2017-09-07 | 2017-09-07 | ATG + Busulfan + Fludarabine | 01 | N | 250030341 | RUXOLITINIB |
| 250006815 | 250004808 | 1.77 | null | Curative (C) | 2014-06-11 | 2014-06-12 | Rituximab | 2 | null | 250030341 | RAVVA TRIAL |
| 250006817 | 250004810 | 1.73 | 67.2 | Palliative (P) | 2016-04-23 | 2016-04-23 | Azacitidine | Y | N | 250030354 | RUXOLITINIB |
| 250006818 | 250004811 | 1.62 | 92.3 | Palliative (P) | 2017-11-27 | 2017-11-27 | CHOP R - 21 days | N | N | 250030362 | RUXOLITINIB |
| 250006819 | 250004811 | 1.72 | 75.8 | Palliative (P) | 2015-08-25 | 2015-09-07 | Trial Unspecified | N | N | 250030362 | TRIAL |
| 250006820 | 250004811 | 1.82 | 95 | Palliative (P) | 2014-04-04 | 2014-04-04 | RUXOLITINIB | N | N | 250030362 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 250006821 | 250004812 | 1.64 | 82 | Adjuvant (A) | 2014-03-04 | 2014-03-11 | Trial Unspecified | 02 | Y | 250030369 | GEMCARBO |
| 250006822 | 250004812 | 1.71 | null | Palliative (P) | 2014-03-20 | 2014-03-20 | ANAGRELIDE | Y | N | 250030369 | NOT MATCHED |
| 250006823 | 250004813 | 1.69 | 76 | Palliative (P) | 2017-11-17 | 2017-11-26 | ANAGRELIDE | N | N | 250030373 | TRIAL |
| 250006824 | 250004814 | 1.62 | 0 | Radical (R) | 2014-06-03 | 2014-06-11 | RUXOLITINIB | N | N | 250030375 | ANAGRELIDE |
| 250006825 | 250004815 | 1.52 | 72.5 | Palliative (P) | 2016-06-07 | 2016-06-07 | PEG INTERFERON | 02 | N | 250030377 | RUXOLITINIB |
| 250006826 | 250004816 | 1.74 | 0 | Disease modification (D) | 2018-01-29 | 2018-02-14 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 250030378 | NOT MATCHED |
| 250006827 | 250004817 | 1.57 | 83.65 | Neo-adjuvant (N) | 2017-09-30 | 2017-10-02 | RUXOLITINIB | null | N | 250030385 | RUXOLITINIB |
| 250006828 | 250004818 | 1.78 | null | Curative (C) | 2014-09-24 | 2014-10-15 | RUXOLITINIB | 02 | N | 250030386 | BENDAMUSTINE + RITUXIMAB |
| 250006829 | 250004818 | 1.75 | null | null | null | 2018-07-22 | Busulfan Oral | null | N | 250030386 | TRIAL |
| 250006830 | 250004819 | null | 74.3 | Not known (9) | null | 2016-02-05 | CHOP R - 21 days | null | N | 250030394 | BENDAMUSTINE + RITUXIMAB |